Guselkumab for the Treatment of Crohn's Disease: Induction Results From the Phase 2 GALAXI-1 Study

In this Journal Club video module, Jamie Brogan, NP, from Northwestern, discusses findings from the Phase 2 GALAXI-1 Study, which evaluated guselkumab, a selective IL-23p19 antagonist, for the treatment of moderate-to-severe Crohn’s disease. This randomized, placebo-controlled study assessed intravenous guselkumab at doses of 200 mg, 600 mg, and 1200 mg, alongside ustekinumab and placebo. At week 12, the results demonstrated significant reductions in Crohn’s Disease Activity Index (CDAI) scores among patients receiving guselkumab compared to those in the placebo group.

Clinical remission was achieved in up to 57% of patients who received the 200 mg IV dose, with additional improvements in biomarker and endoscopic responses. These findings support the 200 mg IV dosing regimen for Phase 3 clinical trials. For more details, visit the GHAPP website or download the GHAPP ACE mobile app for more educational content.